Fangfang Duan, Xin Hua, Xiwen Bi, Shusen Wang, Yanxia Shi, Fei Xu, Li Wang, Jiajia Huang, Zhongyu Yuan, Yuanyuan Huang
BACKGROUND: To explore whether specific clinicopathological covariates are predictive for a benefit from capecitabine maintenance in early-stage triple-negative breast cancer (TNBC) in the SYSUCC-001 phase III clinical trial. METHODS: Candidate covariates included age, menstrual status, type of surgery, postoperative chemotherapy regimen, Ki-67 percentage, histologic grade, primary tumor size, lymphovascular invasion, node status, and capecitabine medication...
May 6, 2024: Breast: Official Journal of the European Society of Mastology